,124 Mechanistically, pharmacological inhibition with fatostatin and genetic SREBP knockdown suppresses tumor growth through the downregulation of SRY-box transcription factor 9 (SOX9), a key marker in early pancreatic neoplasm development.124. Here, SOX9 is linked to pancreatic neoplasm.